Pfizer sees potential in GCPR research

1 September 2020
2020_biotech_lab_vial_research_big

Strasbourg, France-based G Protein-Coupled Receptors (GPCR) pioneer Domain Therapeutics has expanded a research collaboration with New York’s Pfizer (NYSE: PFE).

Domain, which has teams working in both France and Canada, is focused on the discovery and development of new drugs in immuno-oncology, neurology and rare diseases.

The collaboration aims to profile downstream signaling pathways of a set of GPCRs potentially involved across multiple therapeutic areas.

Domain is eligible to receive unspecified upfront payments as well as R&D support, plus as potential discovery and milestone payments for future Pfizer programs which result from the work.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology